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Background: HTLV-1 causes proliferation of clonal populations of infected T cells in vivo, each clone defined by a
unique proviral integration site in the host genome. The proviral load is strongly correlated with odds of the
inflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). There is evidence that
asymptomatic HTLV-1 carriers (ACs) have a more effective CD8 + T cell response, including a higher frequency of
HLA class I alleles able to present peptides from a regulatory protein of HTLV-1, HBZ. We have previously shown
that specific features of the host genome flanking the proviral integration site favour clone survival and spontaneous
expression of the viral transactivator protein Tax in naturally infected PBMCs ex vivo. However, the previous studies were
not designed or powered to detect differences in integration site characteristics between ACs and HAM/TSP patients.
Here, we tested the hypothesis that the genomic environment of the provirus differs systematically between ACs and
HAM/TSP patients, and between individuals with strong or weak HBZ presentation.
Methods: We used our recently described high-throughput protocol to map and quantify integration sites in 95 HAM/
TSP patients and 68 ACs from Kagoshima, Japan, and 75 ACs from Kumamoto, Japan. Individuals with 2 or more HLA
class I alleles predicted to bind HBZ peptides were classified ‘strong’ HBZ binders; the remainder were classified ‘weak
binders’.
Results: The abundance of HTLV-1-infected T cell clones in vivo was correlated with proviral integration in genes and
in areas with epigenetic marks associated with active regulatory elements. In clones of equivalent abundance, integra-
tion sites in genes and active regions were significantly more frequent in ACs than patients with HAM/TSP, irrespective
of HBZ binding and proviral load. Integration sites in genes were also more frequent in strong HBZ binders than weak
HBZ binders.
Conclusion: Clonal abundance is correlated with integration in a transcriptionally active genomic region, and these
regions may promote cell proliferation. A clone that reaches a given abundance in vivo is more likely to be integrated
in a transcriptionally active region in individuals with a more effective anti-HTLV-1 immune response, such those who
can present HBZ peptides or those who remain asymptomatic.
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Human T cell lymphotropic virus-type 1 (HTLV-1) is es-
timated to infect over 10 million people [1], and is en-
demic in sub-Saharan Africa, the south islands of Japan,
the Caribbean and parts of South America. HTLV-1 is
primarily found in CD4+ T cells, where predominantly
only a single copy of the virus integrates into the gen-
ome [2]. The virus is almost 100% cell-associated, and
the viral burden is defined as the fraction of PBMCs that
carry the integrated provirus, termed the proviral load
(PVL). Infected cells proliferate in vivo, producing clonal
populations of cells, each defined by its unique proviral
integration site. The viral regulatory proteins Tax and
HTLV-1 basic leucine zipper factor (HBZ) are known to
drive proliferation of the infected cells [3-5].
More than 90% of HTLV-1-infected individuals remain
lifelong asymptomatic carriers (AC), but 1–6% develop an
aggressive malignancy known as adult T cell leukaemia/
lymphoma (ATLL). A further 0.25 to 4% develop a chronic
inflammatory disease of the central nervous system,
HAM/TSP, characterised by a slowly progressive spastic
paraparesis with pain and neurogenic bladder disturbance
[6]. Risk factors for HAM/TSP include female gender and
high PVL [7].
There is strong evidence that the CD8+ T cell response
is important in limiting PVL, and reducing the risk of
HAM/TSP [8], although innate immunity also plays a
role in the host response to HTLV-1 [9]. Certain HLA
class I alleles are associated with a reduction in PVL and
prevalence of HAM/TSP, in particular HLA-A∗02 and
Cw∗08 in a population from Southern Japan [10]. Tax is
the dominant CD8+ T cell target antigen of HTLV-1
[11,12]: Tax escape mutations in the HLA-A2-restricted
epitope Tax 11-19 are more frequent in individuals with
the HLA-A2 allele [13], and Tax expression is frequently
silenced in the expanded clone in ATLL by mutations in
tax or methylation or deletion of the 5’LTR [14-17]. The
rate of lysis of Tax+CD4+ cells by CD8+ cells has been
inversely correlated with PVL [18], although Tax mRNA
is virtually undetectable directly ex vivo. Individuals who
remain asymptomatic were shown to have a lower PVL
than those with HAM/TSP at a given lysis rate [18], and
had a greater CD8+ T-cell lytic efficiency as measured by
proportion of Tax-specific CTL which degranulate when
exposed to their cognate epitope ex vivo [19].
Unlike Tax, HBZ expression is uniformly maintained
in HTLV-1-infected T cells, including ATLL cells [4],
and this expression correlates with PVL in both ACs and
patients with HAM/TSP [20]. On average, HBZ peptides
bind to HLA class I alleles with lower affinity than Tax
peptides, and the frequency of HBZ-specific CD8+ T
cells [21] is correspondingly lower. HBZ expression may
be maintained because it can drive expansion of an in-
fected clone without presenting a strong target to theCD8+ T cell response. The frequency of HLA class I al-
leles that are predicted to strongly bind HBZ peptides is
greater in ACs than patients with HAM/TSP, and is in-
versely correlated with PVL in each group [21]. These
observations suggest that a CD8+ T-cell response to the
HBZ protein is protective against HTLV-1-associated in-
flammatory disease.
The equilibrium abundance in vivo of a particular
HTLV-1-infected T-cell clone is the result of the interplay
between the proliferation of the clone and counter-
selection by the host response, chiefly the CD8+ T cell
response. Both factors are governed by the program of
proviral expression by the clone. Since the proviral se-
quence is very stable [22], the chief unique attribute of
each HTLV-1-infected T-cell clone is the genomic position
of the integrated provirus – the proviral integration site.
Specific features of the genomic environment of the
HTLV-1 proviral integration site are associated with the
frequency of spontaneous reactivation of Tax expression
ex vivo [23]. Integration in the same transcriptional orien-
tation as a flanking host gene is associated with suppres-
sion of Tax expression: same-sense orientation is more
frequent in high-abundance clones, and more frequent
in vivo than during in vitro infection, suggesting that this
orientation confers a selective advantage by allowing es-
cape from the Tax-specific CD8+ T cell response [23].
There are no published data on the influence of the inte-
gration site environment on HBZ expression.
Since the genomic integration site influences proviral
expression, we reasoned that the selection pressure
exerted by a protective immune response will alter the
abundance of clones which have integration site genomic
environments with certain characteristics. Our previous
reports were neither designed nor powered to examine
the relationship between the integration site environ-
ment and either disease status or host immunogenetics.
In this study, we investigated the differences in integra-
tion site environment between Japanese individuals who
remained AC and those who developed HAM/TSP, and
between those that differed in their capacity to present
HBZ peptides on protective HLA class I alleles. We re-
port that integration sites in genes and active regions are
significantly more frequent in ACs than in patients with
HAM/TSP, even after accounting for clone abundance
and PVL. Integration sites in genes are also more fre-
quent in strong HBZ binders.
Results
Possession of HBZ-binding HLA class I alleles was associated
with reduced HTLV-1 proviral load, but did not affect
oligoclonality of the HTLV-1 infected cell population or total
number of clones by load
We have previously shown that in both ACs and patients
with HAM/TSP in Kagoshima prefecture (Southern Japan),
Table 1 Total patients analysed and integration sites identified
Kagoshima Kumamoto
HAM/TSP AC AC
Number of patients in: Strong HBZ Weak HBZ Total Strong HBZ Weak HBZ Total Strong HBZ Weak HBZ Total
Whole cohort 81 148 229 92 110 202 34 64 98
All LM-PCR 42 62 104 41 59 100 34 64 98
LM-PCR QC pass 39 56 95 30 38 68 24 51 75
Number of UIS* with abundance:
<1 per 10,000 PBMC 7954 12341 20295 1451 5485 6936 4572 9744 14316
1-10 per 10,000 PBMC 10051 12429 22480 2178 2515 4693 1034 1853 2887
>10 per 10,000 PBMC 219 364 583 102 67 169 42 40 82
All 43358 11798 17285
*UIS identified from LM-PCR QC pass samples only.
AC: Asymptomatic carrier, UIS: Unique integration site, QC pass: samples that passed LM-PCR quality controls (QC).
Table 2 HLA class I alleles divided by HBZ epitope
binding status
Strong HBZ binding alleles Weak HBZ binding alleles
A0201, A0206, A0207, A0210 A0101
A2601, A2602, A2603 A0203
A3001 A0301, A0302
A3303 A1101
A2402
A3101
A3201
B3701 B0702
B4001, B4002, B4006 B1301, B1302
B41 B1501, B1507, B1511, B1518
B4403 B2704
B3501, B3520, B3532/B3568
B3802
B3901
B4003, B4009/B4027/B40105
B4601
B4801
B5101
B5201
B5401
B5502, B5504
B5601, B5605
B5801
B5901, B5902
B6701
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bind HBZ epitopes is inversely correlated with PVL [21].
Here, we extended this analysis with a second southern
Japanese AC cohort, from nearby Kumamoto prefecture
(Table 1). The predicted ability of individual HLA class I
A and B alleles to bind HBZ epitopes was determined
using the rank of the top HBZ-binding peptide in the pep-
tide binding prediction software Metaserver, as previously
described [21] (Table 2). We then used linear regression to
analyse the relationship between the number of HBZ-
binding alleles and PVL. In the Kumamoto cohort, as in
the two Kagoshima cohorts, there was an inverse correl-
ation between log PVL and the number of HBZ-binding
alleles (linear regression: slope = -0.12, Table 3). This
correlation was significant in a regression analysis of the
combined Kagoshima cohorts (p = 0.02) as previously
reported, and all three cohorts combined (p = 0.006),
although it did not reach significance in the smaller
Kumamoto cohort alone.
We used our recently developed high-throughput proto-
col [24] to map and quantify the abundance of unique
proviral integration sites in the HAM/TSP cohort and the
two AC cohorts (Table 1). Sufficient DNA was not avail-
able from all subjects, but the median PVL of the HAM/
TSP samples that passed LM-PCR quality controls (QC)
was not significantly different from that of the full HAM/
TSP cohort (Additional file 1: Figure S1A). In the AC co-
horts the median PVL of successfully analysed samples
exceeded that of all ACs, because a proportion of ACs
have a PVL too low to permit accurate quantification [7]
and LM-PCR. Since this reduces the difference in median
PVL between the analysed AC and HAM/TSP cohorts,
our results represent a conservative estimate of the differ-
ence between ACs and patients with HAM/TSP.
Since strong HBZ peptide binding is associated with effi-
cient control of PVL, we tested whether this also altered
the frequency distribution of the infected cell population.
Individuals were designated strong HBZ binders if they
Table 3 Linear regression of HBZ binding alleles to PVL
Outcome Predictor Cohort* n Slope p value Controlling for:
Log PVL # HBZ binding alleles Kagoshima HAM, AC HAM: 221 AC: 200 -0.12 0.021 Age, sex, disease status
Log PVL # HBZ binding alleles Kumamoto AC AC: 98 -0.12 0.28
Log PVL # HBZ binding alleles Kagoshima HAM, AC & Kumamoto AC HAM: 229 AC: 300 -0.13 0.0058 Disease status
*Only individuals who had all the relevant information were included in the regression. Age, sex and disease status were included as factors where possible as
they may vary with PVL.
Age and sex information was not available for the Kumamoto AC cohort.
PVL: proviral load, AC: Asymptomatic carrier, #: number of.
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alleles. The total number of HTLV-1 proviruses mapped
in strong HBZ binders was similar to that in weak HBZ
binders in each cohort (Additional file 1: Figure S1B),
allowing unbiased estimates of clone structure. We esti-
mated the total number of integration site clones in the
blood using our novel in silico approach [25]. The esti-
mated number of clones correlated with PVL in all co-
horts (Figure 1A). There was no significant difference in
estimated total number of clones in the blood, after strati-
fying by PVL, between AC and HAM/TSP cohorts, orFigure 1 Host disease status and HBZ-binding capacity do not alter t
infected Japanese asymptomatic carriers (AC; triangles) from Kagoshima an
Kagoshima were stratified on the basis of predicted HBZ peptide binding a
weak binders, wHBZ, open symbols). Each symbol represents one individua
and samples passing data quality checks were analysed further, as previous
total number of clones in the blood in each subject; the total clone numbe
each cohort both HAM (blue, p = 0.0004) and AC (black, p = 0.0001)). There
between AC and HAM/TSP cohorts (likelihood ratio test, p = 0.30) or betwe
AC and HAM/TSP cohorts (likelihood ratio test, p = 0.06) indicating that the
or HBZ binding status. (B) The oligoclonality index (OCI), which quantifies t
significantly correlated with proviral load in ACs or HAM/TSP (Spearman co
regression line between AC and HAM/TSP cohorts. (C) The median OCI did
(Mann-Whitney U test). Bars denote median +/- interquartile range.between strong HBZ binders and weak HBZ binders
(Figure 1A). The Oligoclonality Index (OCI) quantifies
the diversity in clone abundance in an infected T cell
population: an OCI approaching 1 indicates an essen-
tially monoclonal population, whereas an OCI of 0 indi-
cates that all clones have the same abundance. Consistent
with our previous observations [24], OCI did not correlate
with PVL and did not differ between ACs and HAM/TSP
cohorts (Figure 1B); there was also no difference in OCI
between strong and weak binders of HBZ in any cohort
(Figure 1C).otal unique HTLV-1-infected clones or oligoclonality. HTLV-1
d Kumamoto prefectures and HAM/TSP patients (circles) from
ffinity of host HLA class I alleles (strong binders, sHBZ, filled symbols;
l. Genomic DNA samples were processed by sonication-based LM-PCR
ly described ([23,24]). (A) The DivE method was used to estimate the
r was positively correlated (Spearman correlation) with proviral load in
was no significant difference in slope of the linear regression line
en sHBZ (continuous line) and wHBZ (dashed line) in the combined
re is no systematic difference in total clone number by disease status
he diversity in observed clone abundance in each sample, was not
rrelation) and there was no significant difference in slope of the linear
not differ significantly by HBZ binding status within individual cohorts
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selected in asymptomatic carriers and was associated
with high clonal abundance
Detected integration sites were binned according to their
absolute abundance in 10,000 PBMCs (Additional file 1:
Figure S1C). In this study, we compared the frequency
of transcriptionally active sites between ACs and HAM/
TSP patients, after stratifying by host HBZ binding
strength and absolute clonal abundance. There was no
significant difference in the genomic environment of in-
tegration sites between the AC cohorts from Kumamoto
and Kagoshima (Additional file 1: Figure S2B, Additional
file 1: Figure S3A), which enabled combination of the
two cohorts for further statistical analysis. We previouslyFigure 2 Transcriptionally active integration sites associate with AC s
integration sites from Japanese asymptomatic carriers (AC, black triangles)
TSP patients (blue circles, from Kagoshima). Integration sites were stratified
class I alleles (strong binders, sHBZ, filled symbols; weak binders, wHBZ, op
versus an in silico generated random integration site dataset. (A) AC individ
proportion of integration sites in genes than HAM/TSP patients (chi-square
correlated with clone abundance only in individuals with HLA class I alleles
trend). (B) Asymptomatic carriers had a higher frequency than HAM/TSP of
10 Kb of integration sites (Mann-Whitney U test), and (C) a higher frequenc
mark frequency near integration sites in a bin is divided by frequency near
marks, associated with constitutively heterochromatic DNA. Spearman corre
frequency and log absolute abundance. Statistical comparisons AC vs HAM
p > 0.01, ** 0.01 > p > 0.001, *** p < 0.001.reported that the proportion of integration sites located
within a gene and in active genomic regions increased in
clones which had a higher absolute abundance; conversely
that high abundance clones had a reduced frequency of
sites modified with inhibitory epigenetic marks [24]. Here,
we also observe significant correlations between clonal
abundance and integration in a gene and frequency of
epigenetic marks associated with active genomic regions
(Figure 2, Additional file 1: Figure S3).
The proportion of integration sites within genes was
significantly higher in ACs than in HAM/TSP patients
(Figure 2A). The proportion of integration sites within genes
did not correlate with PVL (Additional file 1: Figure S2A),
suggesting that the difference between ACs and patientstatus and clone abundance in weak HBZ binders. HTLV-1 unique
from Kagoshima and Kumamoto were compared to those from HAM/
on the basis of predicted HBZ peptide binding affinity of host HLA
en symbols) and binned by absolute abundance. Data is expressed
uals (Kagoshima and Kumamoto cohorts combined) had a greater
d test). Percentage of clones with integration sites in genes was
which could not bind HBZ (arrow, significant chi-squared test for
H3K4me2 marks, enriched in transcriptionally active areas, within
y of H3K4me1 marks, associated with enhancers. Mean epigenetic
random sites. (D) In contrast, AC had a lower frequency of H3K9me3
lation shows a significant (arrow) association between epigenetic mark
by Mann-Whitney U test after correction for multiple testing: * 0.05 >
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PVL in ACs. There was no significant difference between
ACs and patients with HAM/TSP in the proportion of inte-
gration sites in the same transcriptional orientation as the
nearest host gene (Additional file 1: Figure S2C) or nearby
transcriptional start site (Additional file 1: Figure S2D).
Compared to patients with HAM/TSP, integration sites
from ACs had higher counts of H3K4me2 and H3K27ac
marks within 10 Kb (indicating active regulatory regions and
open chromatin; Figure 2B, Additional file 1: Figure S3B)
and higher counts of H3K4me1 (associated with enhancers;
Figure 2C). Conversely, integration sites had higher counts
of H3K9me3 (associated with constitutively repressed chro-
matin) in patients with HAM/TSP than ACs (Figure 2D).
There was no difference in the frequency of H3K27me3
marks, which are associated with facultative heterocho-
matin (Additional file 1: Figure S3C). Within genes, inte-
gration sites marked by H4K20me1 (enriched at 5′ ends
of actively expressed gene bodies) were more frequent
in ACs (Additional file 1: Figure S3D), but the percent-
age of integration sites marked by H3K36me3 (enriched
at 3′ ends of actively expressed gene bodies) did not
consistently correlate with either clone abundance or
disease status (Additional file 1: Figure S3E). The in-
creased frequency of active sites and sites in genes in
AC individuals was also significant when the character-
istics of all integration sites within a patient were aver-
aged, and the cohorts analysed at the patient level
(Additional file 1: Figure S4).
Since transcriptional activity of the genome is corre-
lated with gene density, we used a multivariable logistic
regression model to simultaneously test the independ-
ence of association of integration in a gene, active region
and heterochomatin with disease status. This association
was tested both at the level of individual integration
sites, and using a single value per patient representing
the averaged integration sites from that patient. The re-
sults showed that integration within a host gene and
within active and inhibitory genomic regions were each
independently associated with disease status, after control-
ling for clone abundance and host PVL and predicted HBZ
binding affinity (Table 4 and Additional file 1: Figure S3F).Table 4 Proviral integration within genes and active genomic
Data n Outcome
Integration sites AC: 29083 HAM/TSP: 43358 AC vs HAM
Patients AC: 143 HAM/TSP: 95 AC vs HAM
Additional factors controlled in multiple logistic regression model: Host HBZ bindin
site) or log average absolute clone abundance (per patient).
*Percent of integration sites in gene per patient in patient-level analysis.
#: Number of specified epigenetic marks within 10 Kb of integration site. Averaged
OR: Odds ratio, AC: Asymptomatic carrier.Controlling for HBZ affinity using counts of HBZ bind-
ing alleles per patient, rather than a strong/weak desig-
nation, gave a very similar significance and odds ratio.
We next compared the frequency of transcriptionally
active sites between individuals with strong or weak HBZ
binding potential. Integration sites from HBZ strong
binders were more likely to be in a gene than those from
weak binders, even when host disease status and clone ab-
solute abundance were taken into account (Table 5); there
was no significant association with frequency of H3K4me2
or H3K9me3 epigenetic marks. There was a similar odds
ratio between strong and weak HBZ binders in the per-
centage of integration sites in a gene per patient, although
at this level of individual patients the association did not
reach statistical significance.
Discussion
At all levels of clone abundance, ACs had a significantly
higher frequency than patients with HAM/TSP of inte-
gration sites within host genes and in genomic regions
marked by activating epigenetic modifications. This en-
richment was associated with disease status per se and
was independent of variation in proviral load. The odds
ratio of this enrichment in each case was modest (~1.1),
however the finding that both integration in a gene and
integration in an active genomic region were independ-
ently associated with AC status strongly suggests a con-
sistent underlying biological mechanism. The question
arises: what are the forces that favour selective survival
of these integration sites (i.e. in active transcribed re-
gions) in ACs?
We previously reported that Tax-silenced proviruses
were more likely to lie in the same orientation as a flank-
ing host gene or nearby upstream transcriptional start site;
we concluded that this effect may be attributed to tran-
scriptional interference [23]. The integration site locations
that inhibit Tax expression were also associated with in-
creased clone abundance. Consistent with these two find-
ings, more abundant clones were less likely to express Tax
[23]. These observations raised the possibility that a pro-
virus integrated in the same orientation as a host gene
might enjoy a selective advantage in individuals with anregions are independently associated with disease status
In gene* # H3K4me2 # H3K9me3
OR 1.08 1.13 0.88
p value 4.2×10-5 4.8×10-7 2.1×10-6
OR 1.12 1.14 1.0
p value 0.010 0.011 1.0
g status and proviral load, and log absolute clone abundance (per integration
per patient in patient-level analysis.
Table 5 Proviral integration within genes and active genomic regions is associated with disease status
Data n Outcome In gene*
Integration sites sHBZ: 27603 wHBZ: 45439 sHBZ vs wHBZ
OR 1.04
p value 0.007
Patients sHBZ: 93 wHBZ: 146 sHBZ vs wHBZ
OR 1.03
p value 0.2
Additional factors controlled in multiple logistic regression model: Disease status and log absolute clone abundance (per integration site) or log average absolute
clone abundance (per patient).
*Percent of integration sites in gene per patient in patient-level analysis.
OR: Odds ratio, sHBZ: strong HBZ binder, wHBZ: weak HBZ binder.
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the strong anti-Tax CD8+ T cell response. However, the in-
tegration site environments associated with Tax silencing
were not those associated with an increased frequency in
ACs compared to HAM/TSP in this study.
A second possibility is that a more efficient cellular
and innate immune response in ACs [8] means that a
clone needs a greater proliferative capacity to reach a
given absolute abundance. Interestingly, we also observe
an increase in the percentage of integration sites in a
gene amongst integration sites from individuals with
strong predicted HBZ binding capacity compared those
less likely to bind HBZ epitopes, particularly in the less
abundant clones. Increasing numbers of HLA class I al-
leles able to present HBZ are associated with decreasing
PVL, suggesting that there is greater control of infected
cells in these patients [21]. Integration sites located in
genes and active genomic regions are associated with in-
creased clone abundance ([24], and this study): we pos-
tulate that these environments support virus-driven cell
proliferation allowing clones to survive under stronger
immune control.
Tax is known to drive proliferation of the infected cell;
could the clones which selectively survive in ACs express
more Tax? We previously observed, in a very small sample
of integration sites (n = 40, [26]), that Tax-expressing
cells had a higher frequency of integration sites in genes.
However, with the advent of high-throughput sequencing,
we have recently shown that clones that spontaneously ex-
press Tax ex vivo have a minor increase in the frequency
of integration in a gene and in regions with activating epi-
genetic marks ([23] and AM, unpublished observations).
Since we have previously observed that more abundant
clones are less likely to express Tax [23], Tax expression is
unlikely to completely account for the success of these in-
tegration site clones. HBZ is also known to drive cell pro-
liferation [4], and integration in a gene or active region
may also promote increased expression of HBZ. To defini-
tively determine, however, whether transcriptionally active
regions promote increased HBZ expression will require
high-throughput sorting and integration site analysis of
HBZ expressing clones directly ex vivo: this is currently
precluded by the difficulty in sorting cells based ondetection of HBZ protein in naturally-infected PBMCs.
The role of the integration site in driving proliferation via
either Tax or HBZ expression is also complicated by the
effect of Tax and HBZ on the expression or function of
each other.
A recent study in primary infection with BLV, a related
retrovirus [27], has shown that early in infection, integra-
tion is favoured in transcriptionally active areas but is
strongly selected against by the host immune response.
Yet in subsequent chronic infection, abundant clones have
a higher frequency of integration sites in transcriptionally
active areas. Similarly, in HTLV-1, the effectiveness of the
initial host response against expressed viral proteins is
likely to define PVL set point, selecting against highly ac-
tive clones. Clones in heterochomatin may also represent
a dead end for the virus, because it may never be re-
expressed. During lifelong chronic infection, however,
surviving clones with integration sites in ‘intermediate’
transcriptionally active areas may have a proliferative
advantage, although other factors (including clone TCR
specificity or immune escape by Tax silencing or timing of
viral expression [16,23,28]) will also contribute to the
relative success of a clone. These transcriptionally active
clones are more common in ACs than HAM/TSP, plaus-
ibly because they compete against the effective host re-
sponse in ACs, or less likely, because they are selectively
lost (by an unknown mechanism) in HAM/TSP.
There are other differences between HAM/TSP pa-
tients and AC individuals, in addition to the effective-
ness of the T-cell immune response, which could alter
the selection of proviral integration site during chronic
infection. For example, in HAM/TSP, proliferation of
HTLV-1-infected T cells may be maintained by IL-2 [29]
and IL-15 [30], which may reduce the advantage con-
ferred by integration sites that increase expression of
proliferation-inducing factors such as HBZ.
Our results reflect systematic differences in the char-
acteristics of HTLV-1 integration sites that persist
in vivo between HAM/TSP patients and ACs. We
propose that these differences are not themselves causa-
tive of the disparate clinical outcomes, but rather they
reflect an underlying difference between patients with
HAM/TSP and ACs in the efficiency of host-mediated
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sive evidence [8].
Two previous studies compared the integration site
environment between ACs and patients with HAM/TSP
and found no differences, or a borderline significant (p =
0.049) difference [24,26]. The difference between these re-
ports and the present study may be attributable to the dif-
ferences in sample size (N = 238 in present study, cp. N =
40 and 24 respectively in [24,26]), the quantitative nature
and greater sensitivity of the present high-throughput
method, or in the ethnicity of the study population (uni-
formly southern Japanese vs. predominantly Caribbean).
The incidence of HAM/TSP is much lower in the Japanese
population (studied here) than in individuals of Caribbean
origin in the previous studies (0.25 vs 3% [31,32]). In the
current study, we excluded differences in LM-PCR effi-
ciency and mean clone abundance as causes of the ob-
served differences between patients with HAM/TSP and
ACs.
Conclusions
The expression levels of Tax and HBZ influence both
the rate of proliferation and the rate of CTL killing of
each infected T-cell clone, and thus its equilibrium
abundance in vivo. The balance between the relative
strength of these opposing effects differ between the two
genes: tax encodes the dominant target of the CTL re-
sponse and is often silenced in abundant clones despite
its capacity to support proliferation, but HBZ expression
is typically maintained and is a poorer target for the
CTL response. We have previously reported features of
the integration site that influence Tax expression but
there are no studies directly linking integration site and
HBZ expression. We show that integration sites within
genes and active genomic regions are more frequent in
AC clones compared to equivalently-sized clones from
HAM/TSP patients, and in individuals who have HLA
class I allelesable to effectively present HBZ peptides to
CTL. We postulate that integration in a transcriptionally
active area may elevate HBZ and/or Tax expression and
increase the equilibrium abundance of a clone. The in-
creased frequency of integration sites observed in tran-
scriptionally active genomic regions in ACs is consistent
with the conclusion that greater proliferation is required
to reach a given clonal abundance under the selection
pressure exerted by an effective anti-HTLV-1 immune
response.
Methods
Subjects
Kagoshima cohort. The study population has been previ-
ously reported [7,10]. Subjects consisted of 229 patients
with HAM/TSP and 202 HTLV-1-infected asymptomatic
carriers randomly selected from blood donors; all wereof Japanese ethnic origin and residing in Kagoshima,
Kyushu, Japan [7,10].
Kumamoto cohort. The study population consisted of
98 HTLV-1-infected asymptomatic carriers from blood
donors in Kumamoto Prefecture, Kyushu, Japan.
Research was carried out in compliance with the Helsinki
Declaration. The study was approved by the Faculty of
Medical and Pharmaceutical Sciences Ethics Review Board,
University Hospital, Kumamoto, Japan (Ethics 149). All pa-
tients gave written, informed consent for the study and for
publication of anonymized results.
HTLV-1 proviral load measurements
HTLV-1 DNA was amplified by quantitative PCR in a
ABI7900HT FAST real time PCR system using FastSYBR
Green (Applied Biosystems) reagents with the Tax-specific
primers SK43 and SK44. A control region in B-actin was
also amplified using ActF and ActR primers. The rat cell
line TARL-2, which contains one integrated copy of the
HTLV-1 provirus, was used to generate a standard curve.
The sample copy number was interpolated from the
standard curve and PVL was expressed as number of in-
fected cells per 100 PBMCs. Proviral load data for the
Kagoshima HAM/TSP and AC cohorts, with TARL-2 as
pX region control, were as previously described ([7]). SK43:
5′CGGATACCCAGTCTACGTGT, SK44: 5′GAGCCGA
TAACGCGTCCATCG, ActF: 5′TCACCCACACTGTGCC
CATCTATGA, ActR: 5′ CATCGGAACCGCTACTTGCC
GATAG.
HLA class I alleles
HLA class I typing of the Kagoshima cohort was reported
previously ([10]). HLA typing of the Kumamoto cohort
was done by Luminex reverse SSOP at the Hammersmith
Hospital, London, UK to 2 digit resolution with ’strings’ of
possible 4 digit resolution alleles. For each individual’s
string of possible alleles, the most frequent 4-digit allele in
the Japanese population (represented by a study of 1018
Japanese individuals [33]) was identified as the most likely
allele. If there were multiple possible alleles with a popula-
tion frequency >3%, all these frequent alleles were retained
as possibilities for the individual. If no allele subtype in the
string was represented in the population study, all alleles
in the string were retained.
Epitope binding prediction
We used the Metaserver algorithm (detailed in [21]) to
predict HLA class I epitopes. Metaserver combines pre-
dicted TAP transport, proteasomal cleavage and HLA–
peptide binding from NetCTL and NetMHC to predict
peptide binding to HLA Class I A and B alleles present in
the Kagoshima and Kumamoto cohorts. For each HLA
class I A or B allele, all HTLV-1 peptides were ranked by
binding score. The rank of the top HBZ peptide was
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ing peptide for a protein is a more robust method for
comparisons between alleles than affinity [21]. HLA class
alleles where the rank of the top HBZ peptide was < 20
were included as predicted binders of HBZ. A0201 was
also included as a binder (HBZ top rank = 29) as it had
been experimentally shown to present HBZ peptides [34].
For alleles not included in Metaserver, we assessed the
rank of the binding score using NetMHC only. Alleles
where the rank of the top HBZ peptide was < 20 were
added to the predicted binders of HBZ. Approximately
30% of individuals have a detectable CTL response to
HBZ [35]. Individuals with two or more HBZ-binding al-
leles constituted 39% of the combined cohorts, and were
designated ‘strong HBZ binders’ representing individuals
who were most likely to be able to mount an HBZ-specific
response.High-throughput linker-mediated PCR identification of
proviral integration sites
Integration site analysis was carried out on samples from
patients with HAM/TSP and ACs from the Kagoshima
cohort where sufficient genomic DNA was available
(HAM/TSP, n = 104; AC, n = 100). To maximise statis-
tical power and to test for reproducibility, we also ana-
lysed DNA of ACs from a neighbouring prefecture in
Japan, Kumamoto (n = 98).
HTLV-1 integration sites were mapped and their
abundance quantified as previously described ([23,24]).
Genomic DNA from peripheral blood mononuclear
cells was randomly sheared by sonication and ligated
to a partially double-stranded DNA adaptor that incor-
porated a 6 nt barcode, a reverse sequencing primer
site and the P7 sequence for paired-end sequencing.
Two rounds of nested PCR were performed between
the HTLV-1 LTR and the adaptor, adding a paired end
P5 sequence in the LTR primer. The resulting ampli-
cons were combined into libraries of up to 42 samples
and sequence data were acquired on an Illumina GAII
or HiSeq platform with paired-end 50 bp reads and a
6 bp index (barcode) read. Paired reads were aligned to
a human genome reference (build 18, excluding haplo-
type and “random” chromosomes) using ELAND. A
random set of integration sites was derived from ~
190,000 50 bp human genome sequences generated
using Galaxy, and aligned to the same human genome
reference to control for any bias due to alignment
limitations.
Unique integration sites (defined by Read1) were
quantified on the basis of number of distinct shear sites
identified (determined from paired Read2) and calibrated
to provide a count of number of sequenced sister cells
per clone. The absolute abundance (Aabs) of a T cellclonal population, defined by a single HTLV-1 integra-
tion site, was calculated as follows:
Aabs ið Þ ¼ SiXT
i¼1Si
 100  PVL
where Si is the number of sister cells of the ith clone, T is
the total number of observed clones in the patient, and
PVL is the number of infected cells per 100 PBMC in the
patient. Clones were assigned to absolute abundance ranges
of <1 per 104 PBMC, 1-10 per 104 PBMC, >10 per 104
PBMC. LM-PCR integration site data sets for each patient
were subjected to successive quality control filters as previ-
ously described ([23,24]); LM-PCR was designated ‘success-
ful’ and the data included in further analysis only when the
sample contained a minimum of 50 sister cells, a minimum
of 15 clones, an average of more than 15 sequence reads
per sister cell.
Oligoclonality index
To measure the diversity of clone abundance in the in-
fected cell population from each individual, we used the
oligoclonality index [24] which is based on the Gini
Index. This index measures the non-uniformity of the
distribution of clone abundance: a value of 0 indicates
that all clones have the same abundance and 1 is an
upper bound where the proviral load effectively consists
of a single clone.
Estimating total number of clones in the blood
Estimation of total numbers of clones in the blood (ob-
served and unobserved) was carried out using a computa-
tional diversity estimation approach (DivE), as described
previously [25]. Briefly, many mathematical models were
fitted to species-accumulation data, and to successively
smaller nested subsamples thereof. Novel criteria were
used to score models in how consistently they can repro-
duce existing observations from incomplete data. The esti-
mates from the best performing models were aggregated
(using the geometric mean) to estimate the number of
clones in the circulation.
Genetic and epigenetic analysis of integration site
Analysis of the genomic region surrounding the integra-
tion site was carried out as previously described ([23,24]).
Specifically, the following attributes were identified for
each integration site: location within/outside a transcrip-
tional unit and orientation of the provirus versus that
gene, proximity to a CpG island, and counts of selected
histone marks within a 10 Kb window around the integra-
tion site. Locations of transcriptional units were retrieved
from the NCBI (ftp.ncbi.nih.gov/gene/), CpG island data
from UCSC tables [36], and histone marks from ChIP-seq
experiments on primary CD4+ T cells (detailed in [24]).
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of specific relevant annotations using the R package hiAn-
notator (http://malnirav.github.com/hiAnnotator), kindly
provided by N. Malani and F. Bushman (University of
Pennsylvania, USA). An integration site was designated as
being in an area enriched in a particular histone mark if
there were more counts of the mark within a window of
10 Kb around the integration site than around 90% of
random sites.
Statistical analysis
Statistical tests were performed using R version 2.15
(http://www.R-project.org/). A multivariable linear reg-
ression model was used to compare log PVL with the
number of HBZ-binding HLA alleles per individual, taking
into account disease status, as well as age and sex in the
Kagoshima cohort-only analysis as these have been sug-
gested to vary with PVL. Differences in OCI, PVL and
total number of sisters between cohorts were analysed by
non-parametric Mann-Whitney U tests as distributions
were non-normal. Spearman correlation was used to de-
termine the correlation in each cohort between log PVL
and either log estimated number of clones in the blood or
OCI. A likelihood ratio test was used to compare a null
multivariable linear regression model associating log clone
number with log PVL, disease status and HBZ binding
capacity to an alternative model which added an inter-
action term between PVL and HBZ binding capacity. This
allowed a test of whether the association between total
clones in the blood and PVL differed with HBZ binding
capacity. A second likelihood ratio test compared the
same null model with a different alternative model includ-
ing an interaction term between log PVL and disease sta-
tus. This method was repeated for the association of OCI
with log PVL.
In the genomic environment analysis, integration sites
were grouped by absolute abundance range, and by the
prefecture, disease status and HBZ binding status of the
patient. For integration site data statistical analysis, the
two AC cohorts were combined into a single AC group
as they showed very similar integration site characteris-
tics. Within subsets, the proportion of integration sites
located within genes was plotted as odds ratio compared
to random integration sites. Chi-squared tests were used
to compare the total numbers of UIS lying inside or out-
side genes at each absolute abundance bin level. A chi-
squared test for trend was used to measure the significance
of a trend within a cohort across bins of increasing abun-
dance. We plotted the mean number of a specified epigen-
etic mark within a 10 Kb window around integration sites
within a group (N) divided by the mean number of that
mark within 10 Kb of in silico random sites (N random).
Mann-Whitney U tests were used to compare the num-
bers of specified epigenetic marks near integration sitesfrom ACs versus HAM/TSP patients. Spearman correl-
ation was used to test the association between log abso-
lute abundance of an integration site clone and the
frequency of a specified epigenetic mark within 10 Kb
of the integration site.
Correction for multiple comparisons was made using a
Bonferroni-Holm correction to control the family-wise
error rate for each set of tests (Mann-Whitney, Spearman)
carried out across all analysed epigenetic marks and in-
tegration site subsets. Two epigenetic marks (H3K9ac,
H3K4ac) were analysed but not reported as their results
were very similar to reported ones; the p values from their
analyses were included in the calculation of the Bonferroni-
Holm correction. Correction for multiple comparisons was
also made across subsets in the analyses (Chi-square, Chi
square test for trend) of integration sites in genes.
A multivariable logistic regression model was used to
test whether disease status was independently associated
with integration site in a gene, active genomic region and
inhibitory genomic region at the integration site level (all
integration sites used in analysis) or patient level (charac-
teristics of integration sites averaged per patient). Host
HBZ binding status and PVL, as well as log absolute clone
abundance were controlled as additional factors in the
model as these may vary with disease status and integra-
tion site environment. A multivariable logistic regression
model was also used to test the association of integration
in the same orientation as a gene or TSS with disease sta-
tus (controlling for HBZ binding status, PVL and clone
abundance). A further multivariable logistic regression
tested the association of host HBZ binding status with in-
tegration in a gene (controlling for disease status and
clone abundance) at the patient and integration site level.
Additional file
Additional file 1: Figure S1. Clone sister numbers, PVL and abundance
classification in sequenced samples. Figure S2. Integration in a gene
does not vary by viral load or AC cohort and there is no association of
disease status of orientation with respect to flanking gene. Figure S3.
Integration in transcriptionally active regions is more frequent in
asymptomatic controls than HAM/TSP patients. Figure S4.
Transcriptionally active integration sites are more frequent in AC than
HAM/TSP patients.
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